About 100 reports

  • SAFETY PROFILE OF HALAVEN IN THE THIRD-LINE TREATMENT OF METASTATIC BREAST CANCER
  • SAFETY OF ABRAXANE MONOTHERAPY IN THE TREATMENT OF METASTATIC BREAST CANCER

ipage=##& xml=##& quest=##& rid=##& section=##& sequence=-##& pdf=##& dn=## [Accessed February ##, 2017].

  • Breast Cancer
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Intended for one-time use. ##.

  • Breast Cancer
  • World
  • Forecast
  • Boston Scientific Corporation
  • Hologic, Inc.

BIOTECH PHARMACEUTICAL BOEHRINGER- INGELHEIM inflammation, and autoimmunity (RIA); neuroscience; and gastrointestinal tract.

  • Breast Cancer
  • World
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.

From age ## to ##, the risk is ## in ##, or ##. ##%.

  • Breast Cancer
  • World
  • Market Size
  • AbbVie Inc.
  • AstraZeneca PLC

Low ## Low ## ## ## ## ## High ## ## ## ## High R& D High Low ## ## ## ## ## Upcoming mAbs STRATEGY STRENGTH MYLAN BUSINESS OVERVIEW Mylan was established in 1961 and is headquartered in Pennsylvania, US.

  • Breast Cancer
  • Amgen Inc.
  • Biocon Limited
  • Mylan Inc.
  • Roche Group

These instruments are intended for endoscopic gastrointestinal biopsy and should not be used for any purpose other than their intended function.

  • Breast Cancer
  • World
  • Forecast
  • Boston Scientific Corporation
  • Hologic, Inc.
  • 5.2 ONCOLOGY TEST VOLUME
  • Rural China - Cancer Screening Sites by Cancer Type (Number), 2013

In addition, a project has been introduced into urban areas in China from 2012 and targets screening for lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer and liver cancer.

  • Breast Cancer
  • Cancer
  • China
  • East Asia
  • OriGene Technologies, Inc.
  • SAFETY OF AVASTIN IN FIRST-LINE METASTATIC BREAST CANCER

Surgery; ##(##): ##-##.

  • Breast Cancer
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • Market drivers
  • Vendor landscape

You can easily book an appointment with one online.

  • Breast Cancer
  • Alcon, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • 4.3.7 TASELISIB - GENENTECH
  • 3.1.7 HALAVEN (ERIBULIN MESYLATE) - EISAI

The most common Grade III-IV AEs in the taselisib arm were gastrointestinal disorders (##. ##%), infections (##. ##%), and skin/ subcutaneous tissue disorders (##. ##%).

  • Breast Cancer
  • World
  • Market Size
  • AstraZeneca PLC
  • Roche Group

Strategic Recommendation ## ##.

  • Breast Cancer
  • North America
  • World
  • Market Size
  • GE Healthcare Limited
  • 9 Appendix

Treatment of exemestane with entinostat was well tolerated, and the most frequent AEs were fatigue, gastrointestinal disturbances and hematologic abnormalities.

  • Breast Cancer
  • Southeast Asia
  • World
  • Market Size
  • Novartis AG

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Breast Cancer
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Beijing Novartis Pharma Ltd

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Breast Cancer
  • China
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • Shenzhen Main Luck Pharmaceuticals Inc.

Other symptoms include retrosternal pain, weight loss, hematemesis (vomiting blood) and melena (black feces associated with gastrointestinal hemorrhage).

  • Breast Cancer
  • World
  • Market Size
  • Celgene Corporation
  • Merck & Co., Inc.

The double-balloon " push-pull" technique allows visualization and biopsy of the entire gastrointestinal tract.

  • Breast Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

The double-balloon " push-pull" technique allows visualization and biopsy of the entire gastrointestinal tract.

  • Breast Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

OTHER PRODUCTS ARE IN DEVELOPMENT IN RESPIRATORY CONDITIONS, BACTERIAL INFECTIONS, CNS/ PAIN, AND GASTROINTESTINAL DYSFUNCTION.

  • Breast Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

IN ADDITION, THE STUDY SHOWED THIS ADC HAS MANAGEABLE NEUTROPENIA AND GASTROINTESTINAL TOXICITIES.

  • Breast Cancer
  • North America
  • United States
  • Market Size
  • Seattle Genetics, Inc.
  • 5.11 ATEZOLIZUMAB - ROCHE

Treatment of exemestane with entinostat was well tolerated, and the most frequent AEs were fatigue, gastrointestinal disturbances and hematologic abnormalities.

  • Breast Cancer
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

Treatment of exemestane with entinostat was well tolerated and the most frequent AEs were fatigue, gastrointestinal disturbances and hematologic abnormalities.

  • Breast Cancer
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

Surgery, ##(##): ##-##.

  • Breast Cancer
  • Demand
  • Market Size
  • AstraZeneca PLC
  • Pfizer Inc.

Surgery, ##(##): ##-##.

  • Breast Cancer
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

Surgery, ##(##): ##-##.

  • Breast Cancer
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

Surgery, ##(##): ##-##.

  • Breast Cancer
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

Surgery, ##(##): ##-##.

  • Breast Cancer
  • World
  • Demand
  • Market Size
  • Novartis AG

One unit refers to one Biopsy Forceps.

  • Biopsy
  • Breast Cancer
  • Clinical Trial
  • Medical Device
  • GlobalData's company

Surgery, ##(##): ##-##.

  • Breast Cancer
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novartis AG
  • Pfizer Inc.

Multiple applications by one applicant in the retail offering was treated as one application with respect to the maximum application limit.

  • Breast Cancer
  • Targeted Therapy
  • Norway
  • United States
  • Product Initiative
  • Gastrointestinal Stromal Tumor (GIST)
  • Products under Development by Companies, H2 2017

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2017 Summary According to the recently published report ’Tyrosine Protein Kinase CSK - Pipeline Review, H2 2017’; Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC...

  • Breast Cancer
  • Cancer
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.